Cadrenal Therapeutics Issues Q2 2026 Financial Results

What Happened
Cadrenal Therapeutics, Inc. announced financial information for the quarter ended June 30, 2026. On August 13, 2026 the company issued a press release with those results and filed a Current Report on Form 8-K (Item 2.02) disclosing the release; the press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Date filed: August 13, 2026.
• Reporting period: quarter ended June 30, 2026.
• Disclosure type: Item 2.02 (Results of Operations and Financial Condition); press release attached as Exhibit 99.1.
• The 8-K indicates the company provided financial information in the press release (read the attached release for the full figures).

Why It Matters
Quarterly financial results (earnings, revenue, cash position and related metrics) are material for investors because they affect valuation, liquidity assessments and short-term stock performance. This filing signals Cadrenal has released its latest quarterly results; retail investors should review the attached press release (Exhibit 99.1) and the company’s subsequent SEC filings for detailed revenue, net income/loss, cash balance and any guidance or commentary from management.